Cannabis and Cannabinoid Research最新文献

{"title":"<b>Quantification of 14 Major and Minor Cannabinoids with Absorbance</b>-<b>Transmittance Excitation</b>-<b>Emission Matrix Spectroscopy and Machine Learning</b>.","authors":"Mostafa A Elhendawy, Adam M Gilmore, Mohamed M Radwan, Elsayed A Ibrahim, Amira S Wanas, Adel A Marzouk, Suman Chandra, Murrell Godfrey, Jana B Hildreth, A Edward Robinson, Mahmoud A ElSohly","doi":"10.1177/25785125261449640","DOIUrl":"10.1177/25785125261449640","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Cannabis plants (&lt;i&gt;Cannabis sativa&lt;/i&gt;) contain a diverse group of terpenophenolic compounds known as phytocannabinoids, with 131 cannabinoids identified to date. Rapid and low-cost analytical approaches capable of quantifying both major and minor cannabinoids are increasingly important for research, quality control, and regulatory applications. This study evaluates the patented Absorbance-Transmittance Excitation-Emission Matrix (A-TEEM™) spectroscopic technique as a fast and reliable alternative to conventional chromatographic methods. A-TEEM integrates ultraviolet-visible absorbance and fluorescence measurements while correcting for absorbance-dependent inner-filter effects, enabling linear relationships between fluorescence intensity and analyte concentration. The primary objective was to calibrate and validate machine learning models using A-TEEM data for cannabinoid quantification, benchmarked against a validated high-performance liquid chromatography-photodiode array (HPLC-PDA) reference method.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;A total of 49 dry cannabis flower extracts were analyzed using the A-TEEM technique to quantify 14 cannabinoids. Spectral data generated by A-TEEM were directly compared with concentration data obtained from an established and validated HPLC-PDA method. Extreme gradient boosting regression models were developed using HPLC-PDA results as reference values to predict cannabinoid concentrations from A-TEEM spectral data and to evaluate quantitative performance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The A-TEEM method demonstrated rapid, robust, and sensitive quantification of all 14 target cannabinoids. Model performance metrics, including coefficients of determination (&lt;i&gt;R&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt;) and limits of detection (LOD) and limits of quantification (LOQ), are scaled proportionally with the maximum cannabinoid concentrations present in the samples. For major cannabinoids exceeding 0.35% concentration, the mean combined cross-validation and validation &lt;i&gt;R&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; reached 0.994 ± 0.005, with mean LOD and LOQ values of 0.0146% and 0.0442%, respectively. Cannabinoids present between 0.35% and 0.1% showed mean LOD/LOQ values of 0.00278% and 0.00842%, while minor cannabinoids below 0.1% exhibited even lower LOD/LOQ values of 0.0004% and 0.00128%, respectively. In addition, A-TEEM concentration profiles enabled clear qualitative and quantitative differentiation of three cannabis chemovars: tetrahydrocannabinol (THC)-dominant, cannabidiol (CBD)-dominant, and THC-CBD-intermediate hybrids.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The A-TEEM technique provides a sensitive, rapid, and cost-effective approach for the qualitative and quantitative determination of both major and minor cannabinoids in solution. Its analytical performance is comparable to that of the reference HPLC-PDA method while offering substantial advantages in speed, simplicity, and suitability for high-throughput analysi","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261449640"},"PeriodicalIF":2.7,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147947972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Corrigendum to:</i> How Has Japan's Cannabis Control Act Been Amended?","authors":"","doi":"10.1177/25785125261448987","DOIUrl":"https://doi.org/10.1177/25785125261448987","url":null,"abstract":"","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261448987"},"PeriodicalIF":2.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147833954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis Products and Contaminant Detection: Critical Review of Regulatory Oversight and Analytical Methodologies.","authors":"Danna Valeria Rosas Pinto, Hui Li, Mingjing Sun","doi":"10.1177/25785125261439008","DOIUrl":"https://doi.org/10.1177/25785125261439008","url":null,"abstract":"<p><strong>Introduction: </strong>Cannabis legalization and consumption in the United States have accelerated over the past decade, resulting in a rapidly diversifying marketplace of medical and adult-use products. As of 2025, medical cannabis is permitted in 47 states, while adult-use markets are authorized in 24 states and the District of Columbia. This expansion underscores the urgent need for robust and consistent safety testing to ensure consumer protection. Despite federal prohibition, states have independently developed their own regulatory frameworks for contaminant testing, leading to wide variability in allowable limits, analyte lists, and method validation requirements.</p><p><strong>Method: </strong>This review critically compares contaminant regulations across U.S. adult-use jurisdictions and evaluates analytical methodologies published between 2020 and 2025 for four major hazard categories: heavy metals, pesticides, mycotoxins, and residual solvents. Emphasis is placed on sample preparation strategies, analytical instrumentation, and method performance parameters relevant to complex cannabis matrices such as flower, concentrates, and infused products.</p><p><strong>Results: </strong>Sample preparation approaches are tailored to matrix complexity and frequently utilize Quick, Easy, Cheap, Effective, Rugged, and Safe (QuEChERS) extraction followed by dispersive solid-phase extraction (dSPE). Cartridge SPE is commonly applied for enhanced cleanup, and immunoaffinity columns is used for selective isolation of aflatoxins and ochratoxin A. Instrumental analysis typically relies on Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) for trace metals, liquid chromatography-tandem mass spectrometry and gas chromatography-tandem mass spectrometry (GC-MS/MS) for pesticide and mycotoxin detection, and headspace GC with flame ionization detection or GC-MS for residual solvent quantification.</p><p><strong>Discussion: </strong>Although current methodologies provide sensitive and reliable detection, inconsistencies in regulatory oversight across jurisdictions limit data comparability and complicate interstate commerce. Establishing harmonized performance criteria, standardized reporting units, and national proficiency testing programs would improve method reliability and consumer confidence. Continued innovation in sample preparation and validated multi-residue methods will be critical as product diversity and testing demands continue to expand.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261439008"},"PeriodicalIF":2.7,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining Cannabis Use Disorder in Administrative Health Data: A Systematic Review of Case Definitions and Validation Approaches.","authors":"Anees Bahji, Mohammad Idris Alemi, Geoffrey Messier, Scott Patten","doi":"10.1177/25785125261437621","DOIUrl":"https://doi.org/10.1177/25785125261437621","url":null,"abstract":"<p><strong>Introduction: </strong>Reliable case definitions (CDs) for cannabis use disorder (CUD) are essential for epidemiologic surveillance, health services research, and policy evaluation. As reliance on health administrative data increases, variation in diagnostic coding practices and limited validation of CDs may undermine the comparability and accuracy of CUD estimates. This systematic review aimed to identify, describe, and critically appraise how CUD has been operationalized within administrative health data sources, with particular attention to coding strategies and validation practices.</p><p><strong>Methods: </strong>Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we systematically searched PubMed, EMBASE, and related databases for studies using <i>International Classification of Diseases</i> (ICD) codes to define CUD in administrative health data. Two reviewers independently screened studies, extracted data on CD components and validation methods, and assessed methodological quality using the Newcastle-Ottawa Scale.</p><p><strong>Results: </strong>A total of 56 studies met the inclusion criteria. Most relied on ICD-9 or ICD-10 diagnostic codes to identify CUD, typically using a one-or-more-code rule, although operational details varied by jurisdiction, coding framework, and observation window. No included study explicitly reported internal or external validation of its CD. Reported prevalence estimates ranged widely, from 0.06% in large administrative cohorts to 76.9% in highly selected clinical populations, reflecting differences in CD construction and study populations.</p><p><strong>Conclusions: </strong>CDs for CUD in administrative data vary substantially and lack empirical validation, limiting their reliability for surveillance and comparative research. The development and validation of standardized, transparent CDs are needed to strengthen cannabis epidemiology and to support reproducible research, health-system planning, and policy decision-making.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261437621"},"PeriodicalIF":2.7,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Tolerability of Low-Dose Full-Spectrum Cannabidiol in Long-Term Virally Suppressed Adults with HIV: A Randomized Double-Blind Placebo-Controlled Trial.","authors":"Clémence Couton, Mathilde Wanneveich, Barbara De Dieuleveult, Chloé Robin, Kossi Ayena, Alicia Harry, Hélène Klein, Véronique Avettand-Fenoel, Laurent Hocqueloux, Lucile Mollet, Thierry Prazuck","doi":"10.1177/25785125261439014","DOIUrl":"https://doi.org/10.1177/25785125261439014","url":null,"abstract":"<p><strong>Introduction: </strong>People with long-term virologically suppressed HIV (PWH) experience chronic inflammation. Beneficial effects such as lower levels of inflammation were reported for cannabis-based medicine, but data on the safety of standardized low-dose full-spectrum cannabidiol (CBD) are limited.</p><p><strong>Methods: </strong>This double-blind randomized placebo-controlled trial (NCT05306249) included 80 ART-treated PWH with undetectable viremia (median time on efficient ART 14 years, median age 54 years), encompassing 30% women. Participants received 1 mg/kg CBD oil twice daily (full-spectrum, tetrahydrocannabinol < 0.3%) or placebo for 12 weeks plus a 4-week follow-up. Primary trial end-point (autophagy gene expression) will be described elsewhere; here we evaluate the treatment impact on prespecified safety outcomes such as hemodynamic with electrocardiograms, HIV immunovirological parameters, and comprehensive assessments of liver and kidney functions, performed using standard blood tests. Mixed-effects models adjusted for baseline age, sex, body mass index, CD4 count and duration of viral suppression assessed longitudinal changes.</p><p><strong>Results: </strong>Of 80 randomized participants, 35 PWH in CBD and 37 in placebo groups completed week 12. No clinically meaningful differences emerged in creatinine, aminotransferases (alanine aminotransferase, aspartate aminotransferase), or conjugated bilirubin. Total bilirubin decreased in the CBD arm vs placebo (mixed effect model considering time, group and time*group, adjusted for covariates, <i>p</i> = 0.046). In exploratory sex-stratified analysis, a significant difference starting at week 12 (-8.0 bpm [95% CI: -15.6; -0.4], <i>p</i> = 0.0425) and persisting at week 16 (-7.9 bpm [95% CI: -14.6; -1.3], <i>p</i> = 0.0191) evidences a lower heart rate in men belonging to the CBD group compared with the placebo group; no change in females. There was no change in plasma viral load, cell-associated HIV-DNA levels, and CD4/CD8 ratio.</p><p><strong>Discussion: </strong>Low-dose full-spectrum GMP-certified CBD was well tolerated over 12 weeks in virally suppressed people with HIV. Observed reductions in total bilirubin and male heart rate are exploratory and warrant confirmation in adequately powered trials incorporating inflammatory biomarkers and pharmacokinetics.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"25785125261439014"},"PeriodicalIF":2.7,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-Related Effects of Cannabis and Cannabinoids on Brain and Behavior.","authors":"Conor H Murray, Joshua Cassarino, Ziva D Cooper","doi":"10.1177/25785125251372061","DOIUrl":"10.1177/25785125251372061","url":null,"abstract":"<p><strong>Introduction: </strong>The effect of cannabis use on health is likely to depend on individual differences. In particular, there is a growing need to understand the impact of cannabis and delta-9-tetrahydrocannabinol (THC) on brain and behavioral health across the lifespan.</p><p><strong>Materials and methods: </strong>We conducted a narrative review summarizing the effects of cannabis and THC across three stages of life: <i>in utero</i>, adolescence, and late adulthood. We also provide an up-to-date report on past 30-day cannabis use and risk perceptions from the National Survey on Drug Use and Health (NSDUH; 2002-2023) during pregnancy, adolescence, and late adulthood. We note that NSDUH data collected during 2020 and since 2021 are not directly comparable to earlier years due to shifts in data collection methods.</p><p><strong>Results: </strong>Recent epidemiological data indicate a potential reversal of both the escalating rates of cannabis use and low perceptions of risk among pregnant women and adolescents. Findings across preclinical and clinical studies support high perceptions of risk for individuals <i>in utero</i> and adolescence, when alterations in brain development indicate potential for susceptibility to neuropsychiatric disorders. The escalating rates of cannabis use and associated low perceptions of risk have shifted to the late adulthood population, which may face unique health risks associated with cannabis use.</p><p><strong>Conclusions: </strong>Our findings emphasize the necessity for clinical and policy recommendations to mitigate the risks associated with cannabis use and to enhance public understanding of its implications on neurodevelopmental and psychiatric disorders. Continued research and educational strategies are essential to address these evolving trends and reduce harm.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"99-113"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A National Survey of Marijuana Use Among U.S. Adults According to Obesity Status, 2016-2022.","authors":"Ray M Merrill","doi":"10.1089/can.2024.0069","DOIUrl":"10.1089/can.2024.0069","url":null,"abstract":"<p><strong>Background and objective: </strong>Research has linked marijuana use with lower body mass index (BMI). The current study explores the correlation between marijuana use on BMI in the general U.S.</p><p><strong>Population: </strong>It reports the prevalence of marijuana in adults in relation to BMI, overall and across the levels of important variables.</p><p><strong>Materials and methods: </strong>This study used a probability sample of U.S. adults 18 years of age and older from the 2016 through 2022 Behavioral Risk Factor Surveillance System, a telephone-administered survey. The survey collects data from a representative sample regarding health-related risk behaviors, chronic health conditions, and use of preventive services. The primary outcome variables are current (at least once in the last 30 days) and daily (at least 20 of the last 30 days) marijuana use.</p><p><strong>Results: </strong>The study sample consists of 735,921 participants in the surveys that completed the optional module on marijuana use. Prevalence of marijuana use in adults doubled during the study period (7.48% to 14.91%). The increase directly corresponds with a shift toward legalization of medical and recreational marijuana. On average, the prevalence of use is 9% higher when medical marijuana is legal and 81% higher when recreational marijuana is legal (vs. not legal). For obese individuals, prevalence of current marijuana use is 35% lower than for nonobese individuals on average. Lower prevalence of marijuana use in obese individuals is consistently observed across the levels of certain demographic variables, employment status, tobacco smoking history, marijuana legalization status, and certain medical conditions (asthma, arthritis, and depression). In 2022, the adjusted odds of current or daily marijuana use are significantly lower and similar among obese (vs. non-obese) (0.68, 0.69, respectively), such that reduced obesity does not require daily use. Similarly, the adjusted odds of current marijuana use decrease in similar fashion to daily marijuana use with higher BMI weight classification.</p><p><strong>Conclusion: </strong>Marijuana use is correlated with lower BMI. As legalization and prevalence of the drug in the U.S. increases, the prevalence of obesity may decline. However, clinicians should view this outcome along with the known health risks associated with marijuana use.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"160-169"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review.","authors":"Justin J Sherman, Daniel M Riche","doi":"10.1177/25785125261425444","DOIUrl":"10.1177/25785125261425444","url":null,"abstract":"<p><strong>Introduction: </strong>This systematic review evaluated randomized controlled trials (RCTs) conducted specifically in participants with diabetes and painful peripheral neuropathy to assess the effectiveness and safety of medical cannabis, isolated cannabinoids, or nationally approved cannabis-based medicines as adjuvant treatment, compared with placebo or baseline.</p><p><strong>Materials and methods: </strong>Controlled clinical studies and RCTs in adults with diabetic peripheral neuropathy were eligible. Animal and <i>in vitro</i> studies were excluded. We searched PubMed, Google Scholar, Cochrane Library, and Scopus and screened 15,377 records; 35 full-text articles were assessed for eligibility, and 4 RCTs were included in the qualitative synthesis.</p><p><strong>Results: </strong>Three of four studies reported statistically significant reductions in neuropathic pain with cannabinoid-based interventions compared with placebo, whereas one trial did not demonstrate superiority. In two trials using vaporized or sublingual Δ9-tetrahydrocannabinol (THC), doses in the range of approximately 16-18 mg were associated with clinically meaningful pain relief in participants. Adverse effects, including dizziness and cognitive symptoms, were common but generally mild-to-moderate, and discontinuations due to adverse effects varied across studies.</p><p><strong>Discussion/conclusion: </strong>Evidence from four small, heterogeneous RCTs suggests that cannabinoid-based therapies may reduce pain in some patients with diabetic peripheral neuropathy; however, the limited number of studies, variability in formulations and comparators, and risk of bias preclude firm conclusions regarding efficacy. Observed THC doses around 16-18 mg/day delivered via vaporized or sublingual routes should be viewed as preliminary, hypothesis-generating ranges rather than definitive recommendations. Larger, contemporary RCTs with rigorous risk-of-bias control, standardized outcomes, and detailed safety reporting are needed.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"114-124"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polysubstance Use Disorders in Individuals with Cannabis Use Disorder: Results from a Nationally Representative Sample (National Epidemiologic Survey on Alcohol and Related Conditions).","authors":"Linas Wilkialis, Soyeon Kim, Ahmed Nabeel Hassan, Bernard Le Foll","doi":"10.1177/25785125251363122","DOIUrl":"10.1177/25785125251363122","url":null,"abstract":"<p><strong>Objective: </strong>Cannabis use disorder (CUD) is one of the most common substance use disorders (SUDs) worldwide and is frequently associated with high rates of polysubstance use; however, despite rising rates of polysubstance use disorders (PUD), the characteristics of individuals with both CUD and PUD remain unclear. This study, therefore, aims to examine social and clinical characteristics of adults diagnosed with CUD and comorbid PUD. It also aims to assess whether psychiatric disorders are linked to higher odds of PUD among individuals with CUD.</p><p><strong>Methods: </strong>Using a nationally representative U.S. dataset, we assessed 972 individuals with past-year DSM-5 CUD, grouped as CUD only, CUD individuals with one additional SUD (CUD + 1), and CUD individuals with two or more SUDs (CUD + 2). Descriptive statistics summarized social and clinical presentations; multivariate logistic regression examined factors contributing to PUD, controlling for clinical diagnoses and childhood maltreatment.</p><p><strong>Results: </strong>Among CUD individuals, 89.3% (<i>n</i> = 868) used at least one other substance in the past year, with 34.2% (<i>n</i> = 332) using two or more. Both the CUD + 1 and CUD + 2 groups experienced significantly more severe childhood maltreatment than CUD only. After adjusting for controls, personality disorders were associated with membership in the CUD + 1 group (odds ratio [OR]: 1.88, <i>p</i> = 0.01); mood disorders were associated with a higher likelihood of being in the CUD + 1 group (OR: 1.50, <i>p</i> = 0.049) and CUD + 2 group (OR: 2.58, <i>p</i> = 0.005).</p><p><strong>Conclusion: </strong>Mood and personality disorders were highly prevalent and linked with PUD in CUD cases. We recommend screening for these disorders in complex CUD cases.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":" ","pages":"170-179"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Consumption of Cannabidiol During Pregnancy Alters Behavior in Mouse Offspring.","authors":"Luis E Gomez Wulschner, Victoria N Chang, Won Chan Oh, Emily Anne Bates","doi":"10.1177/25785125251413416","DOIUrl":"10.1177/25785125251413416","url":null,"abstract":"<p><strong>Background: </strong>Pregnant people use cannabidiol (CBD) to treat nausea, insomnia, anxiety, and pain. However, CBD crosses the placenta and enters the fetal brain, where it can affect several targets important for brain development. While consumption of high doses of CBD during pregnancy has been shown to disrupt offspring neurodevelopment, pain sensitivity, and cognitive behavior in mice, lower doses have not been assessed.</p><p><strong>Methodology: </strong>We administered 10 mg/kg/day CBD by oral gavage to pregnant C57Bl6 mice from embryonic day 5 through birth. We used the puzzle box, the forced swim test, and Hargreaves thermal sensitivity behavior tests and electrophysiology to determine how prenatal CBD exposure affects postnatal behavior and prefrontal cortex physiology.</p><p><strong>Results: </strong>We show that oral consumption of 10 mg/kg/day CBD during pregnancy increases thermal pain sensitivity in male mouse offspring. Furthermore, the same dose impairs cognition and reduces excitability of the prefrontal cortex in female mouse offspring.</p><p><strong>Conclusion: </strong>These data show that lower doses of CBD consumption during pregnancy can impair fetal brain development and postnatal behavior.</p>","PeriodicalId":9386,"journal":{"name":"Cannabis and Cannabinoid Research","volume":"11 2","pages":"130-137"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147467244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}